Research

November 30, 2010
0 Comments

Clinical Results from Phase 1 NP001 Study in the Treatment of ALS

A double-blinded, placebo-controlled, Phase 1, single ascending dose study was performed to assess the safety and tolerability of four single intravenous doses of NP001 in a total 32 individuals with ALS. … Importantly, following a single dose, there was a dose-dependent, statistically significant improvement in blood levels of the biomarker thought to be involved in ALS disease progression; this is a first in ALS. … Miller, M.D., the study’s principal investigator and Medical and Program Director of the Forbes Norris MDA/ALS Research Center, commented, “NP001 appears to have affected the level of a biomarker directly related to ALS pathogenesis in a dose-dependent manner.

Read the full article →
August 9, 2010
1 Comment

Nerve connections are regenerated after spinal cord injury

This is an interesting development, I am sure that researchers will find a way to apply this technique to help develop some treatment for ALS. Researchers for the first time have induced robust regeneration of nerve connections that control voluntary movement after spinal cord injury, showing the potential for new therapeutic approaches to paralysis and [...]

Read the full article →
April 16, 2010
0 Comments

Knopp Neurosciences Presents Further Encouraging Trends in Its Phase 2 Study of KNS-760704 (Dexpramipexole) in ALS

This is really encouraging, there is going to be a new drug In the market soon. Finally an alternative to very expensive Rilutek, I’m so excited… In Part 2 of the study, 92 subjects were re-randomized to receive daily doses of 50 mg or 300 mg of dexpramipexole for 24 weeks. In addition to results [...]

Read the full article →
March 23, 2010
0 Comments

Another Stem Cell Trial To Begin

This is awesome news! In the first federal-government-approved clinical trial of its kind in the U.S., patients with amyotrophic lateral sclerosis (ALS) will be treated with their own stem cells. The aim is to hopefully slow the progress of the fatal, neurodegenerative disease. TCA Cellular Therapy of Covington, a privately held stem-cell research and development [...]

Read the full article →
March 10, 2010
1 Comment

Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis

A new potential treatment on the horizon. I’m so excited! Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that its fast skeletal muscle troponin activator, CK-2017357, has been granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou Gehrig’s Disease. CK-2017357 is [...]

Read the full article →

← Previous Entries